Literature DB >> 24357248

Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.

Naoyoshi Onoda1, Masanori Nakamura, Naoki Aomatsu, Satoru Noda, Shinichiro Kashiwagi, Kosei Hirakawa.   

Abstract

BACKGROUND: Anaplastic thyroid cancer (ATC) is thought to often be transformed from pre-existing differentiated thyroid cancer. It is one of the most aggressive malignancies and has a dismal prognosis due to its resistance to multimodal therapies. Basic exploratory studies using authentic ATC cell lines that retain its clinical features are necessary. We investigated the characteristics of seven ATC cell lines newly established at our institute to confirm their possible utility for basic studies.
METHODS: Seven distinct cell lines from six patients were established. Their molecular characteristics and sensitivities to cytotoxic anti-cancer drugs were investigated and compared with each other, and with the clinical features of the original tumors.
RESULTS: All cells showed extensive chromosomal abnormality and Pax8 expression, indicating human thyroid follicular cell origin. Vascular endothelial growth factor was secreted from all cells, suggesting possible candidacy for targeted therapy. Vimentin was expressed, but E-cadherin expression was lost in all cells but OCUT-1C, which showed different features from those of OCUT-1F derived from the same tumor, suggesting a mixture of cancer cell clones with various degrees of differentiation within a single ATC tumor. Cells were likely to show sensitivity for taxanes, indicating the usefulness of taxanes as the first-line chemotherapy. OCUT-2, a cell line with both B-Raf and PI3 KCA mutation, demonstrated the importance of molecular target-oriented therapy.
CONCLUSIONS: Basic studies using authentic ATC cell lines retaining the clinical features of the original tumor are useful models for investigating the mechanism of anaplastic transformation and exploring novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24357248     DOI: 10.1007/s00268-013-2409-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.

Authors:  Iwao Sugitani; Akira Miyauchi; Kiminori Sugino; Takahiro Okamoto; Akira Yoshida; Shinichi Suzuki
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

2.  BRAF V600E inhibition in anaplastic thyroid cancer.

Authors:  Michael H Rosove; Parvin F Peddi; John A Glaspy
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

3.  Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.

Authors:  Takuya Higashiyama; Yasuhiro Ito; Mitsuyoshi Hirokawa; Mitsuhiro Fukushima; Takashi Uruno; Akihiro Miya; Fumio Matsuzuka; Akira Miyauchi
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

4.  A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Patrick Treseler; Kenneth A Woeber; Orlo H Clark; Francis S Greenspan; Sheila Lindsay; Quan-Yang Duh; Eugene Morita
Journal:  Surgery       Date:  2006-12       Impact factor: 3.982

5.  Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma.

Authors:  Jing Liu; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-10-01

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy.

Authors:  Sebastian Hoffmann; Anette Wunderlich; Ilhan Celik; Katja Maschuw; Iyad Hassan; Lorenz C Hofbauer; Andreas Zielke
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

8.  Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups.

Authors:  Michiko Matsuse; Kensaku Sasaki; Eijun Nishihara; Shigeki Minami; Chisa Hayashida; Hisayoshi Kondo; Keiji Suzuki; Vladimir Saenko; Koh-ichiro Yoshiura; Norisato Mitsutake; Shunichi Yamashita
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

9.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.

Authors:  Y Nobuhara; N Onoda; Y Yamashita; M Yamasaki; K Ogisawa; T Takashima; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

10.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  10 in total

1.  Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.

Authors:  Ana T Pinto; Marta Pojo; Joana Simões-Pereira; Ruben Roque; Ana Saramago; Lúcia Roque; Carmo Martins; Saudade André; José Cabeçadas; Valeriano Leite; Branca M Cavaco
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

2.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

3.  Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Authors:  Iñigo Landa; Nikita Pozdeyev; Christopher Korch; Laura A Marlow; Robert C Smallridge; John A Copland; Ying C Henderson; Stephen Y Lai; Gary L Clayman; Naoyoshi Onoda; Aik Choon Tan; Maria E R Garcia-Rendueles; Jeffrey A Knauf; Bryan R Haugen; James A Fagin; Rebecca E Schweppe
Journal:  Clin Cancer Res       Date:  2019-02-08       Impact factor: 12.531

4.  Nestin expression as an independent indicator of poor prognosis for patients with anaplastic thyroid cancer.

Authors:  Kento Kurata; Naoyoshi Onoda; Satoru Noda; Shinichiro Kashiwagi; Yuka Asano; Hidemi Kawajiri; Tsutomu Takashima; Sayaka Tanaka; Masahiko Ohsawa; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

5.  Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.

Authors:  Naoyoshi Onoda; Masanori Nakamura; Naoki Aomatsu; Satoru Noda; Shinichiro Kashiwagi; Kento Kurata; Shinya Uchino; Kosei Hirakawa
Journal:  Mol Clin Oncol       Date:  2015-01-23

6.  Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).

Authors:  Jung-Hyun Kim; Dana Hyunjung Ahn; Je-Sung Moon; Hyun-Jung Han; Kieun Bae; Kyong-Ah Yoon
Journal:  Vet Q       Date:  2021-12       Impact factor: 3.320

7.  A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.

Authors:  Keisuke Enomoto; Fuyuki Sato; Shunji Tamagawa; Mehmet Gunduz; Naoyoshi Onoda; Shinya Uchino; Yasuteru Muragaki; Muneki Hotomi
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

8.  Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.

Authors:  Koichi Ohno; Tomohiro Shibata; Ken-Ichi Ito
Journal:  Cancer Sci       Date:  2022-07-12       Impact factor: 6.518

9.  Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.

Authors:  Anastasios Maniakas; Ying C Henderson; Hu Hei; Shaohua Peng; Yunyun Chen; Yujie Jiang; Shuangxi Ji; Maria Cardenas; Yulun Chiu; Diana Bell; Michelle D Williams; Marie-Claude Hofmann; Steve E Scherer; David A Wheeler; Naifa L Busaidy; Ramona Dadu; Jennifer R Wang; Maria E Cabanillas; Mark Zafereo; Faye M Johnson; Stephen Y Lai
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

10.  Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.

Authors:  Sae Ishihara; Naoyoshi Onoda; Satoru Noda; Yuka Asano; Yukie Tauchi; Tamami Morisaki; Shinichiro Kashiwagi; Tsutomu Takashima; Masaichi Ohira
Journal:  Int J Oncol       Date:  2019-09-19       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.